BioGaia ABBGLAF 100 PB Ratio is 8.20 as of Jun. 28, 2026, which is 5% below its 10-year median of 8.65. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, BioGaia AB ranks worse than 91.44% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-28), BioGaia AB's share price is $12.20. BioGaia AB's Book Value per Share for the quarter that ended in Mar. 2026 was $1.49. Hence, BioGaia AB's PB Ratio of today is 8.20.
Warning Sign:
BioGaia AB stock PB Ratio (=8.57) is close to 5-year high of 9.51.
The historical rank and industry rank for BioGaia AB's PB Ratio or its related term are showing as below:
BGLAF'
s PB Ratio Range Over the Past 10 Years
Min: 4.21 Med: 8.65 Max: 20.63
Current: 8.57
During the past 13 years, BioGaia AB's highest PB Ratio was 20.63. The lowest was 4.21. And the median was 8.65.
BGLAF's PB Ratio is ranked worse than 91.44% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.81
vs BGLAF: 8.57
During the past 12 months, BioGaia AB's average Book Value Per Share Growth Rate was -21.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -12.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 17.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioGaia AB was 49.40% per year. The lowest was -17.50% per year. And the median was 10.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BioGaia AB PB Ratio Related Terms
BioGaia AB PB Ratio Historical Data
* Premium members only.
The historical data trend for BioGaia AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioGaia AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
BioGaia AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioGaia AB (BGLAF) has a PB Ratio of 8.20 as of Jun. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioGaia AB and its competitors. This is near median its historical median of 8.65. Over the past decade, BioGaia AB's PB Ratio has ranged from 4.21 to 20.63. According to the industry distribution chart, BioGaia AB ranks #844 out of 923 companies in the Drug Manufacturers industry, placing it in the top 91.4%.
Is BioGaia AB's PB Ratio too high?
BioGaia AB's current PB Ratio of 8.20 is near median its 10-year median of 8.65. Over the past 10 years, this metric has ranged from a low of 4.21 to a high of 20.63. The Drug Manufacturers industry median PB Ratio is 1.81. BioGaia AB's value of 8.20 is 353% above this industry median. Based on the distribution chart, BioGaia AB ranks #844 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #844 out of 923 companies for PB Ratio. This places BioGaia AB in the lower half of its industry. The industry median PB Ratio is 1.81. BioGaia AB's value of 8.20 is 353% above this benchmark. Historically, BioGaia AB's own PB Ratio has ranged from 4.21 to 20.63 over the past decade. While the company's 10-year median is 8.65 vs. the industry median of 1.81, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.81, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current PB Ratio of 8.20 is 353% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current PB Ratio is 8.20, which is near median its own 10-year median of 8.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current PB Ratio of 8.20. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current PB Ratio is 8.20, which is near median its 10-year median of 8.65 and 353% above the Drug Manufacturers industry median of 1.81. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current PB Ratio is 8.20 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
PB Ratio: 8.20 (near median its 10-year median of 8.65)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 353% above the Drug Manufacturers median (#844 of 923)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
